Abstract：
Background: Micro RNAs are new diagnostic markers and therapeutic targets in breast cancer research. miR-107 and miR-126 have been reported to be linked with the pathogenesis of breast cancer. The present study investigates the levels of expression of miR-107 and miR-126 in patients with breast cancer to find their correlation with the risk of breast cancer in Amritsar, Punjab, Northwest India. Material and Methods: In total, 200 subjects, 100 patients with breast cancer and 100 controls, were enrolled to screen the expression of miR-107 and miR-126 using quantitative reverse transcription polymerase chain reaction (RT-PCR) technique. The Livak method (2-ΔΔCt) was used to calculate the fold change of the expression of micro RNAs. Student t-test was used to calculate the significant change in the expression of miRNAs in patients as compared with controls. Spearman rank correlation coefficient and ROC were conducted. The value of p < 0.05 was considered to indicate a statistically significant difference. Results: miR-107 was downregulated in patients with breast cancer as compared with controls (fold change = 0.467; p = 0.114) but not statistically significant. The expression of miR-126 was found to be 5.37 times elevated in patients with breast cancer, specifically in stage I and stage III patients (p = 0.009), compared with controls, which may indicate its oncogenic activity. The ROC analyses revealed that miR-126 could be a potential diagnostic marker. In conclusion oncogenic behavior of miR-126 is suggestive of its role in pathogenesis in patients with breast cancer.
摘要：
背景：微小RNA是乳腺癌研究中新的诊断标记和治疗靶点。miR-107和miR-126已被报道与乳腺癌的发病机制有关。本研究调查了miR-107和miR-126在乳腺癌患者中的表达水平，以发现它们与Amritsar乳腺癌风险的相关性。旁遮普,印度西北部。材料和方法：总计，200个科目,100名乳腺癌患者和100名对照者,采用定量逆转录聚合酶链反应(RT-PCR)技术筛选miR-107和miR-126的表达。Livak方法(2-ΔΔCt)用于计算微小RNA表达的倍数变化。使用学生t检验来计算与对照相比患者中miRNA表达的显著变化。进行Spearman秩相关系数和ROC。p<0.05的值被认为指示统计学上显著的差异。结果：与对照组相比，乳腺癌患者的miR-107下调（倍数变化=0.467；p=0.114），但无统计学意义。miR-126的表达在乳腺癌患者中升高了5.37倍，特别是在I期和III期患者中（p=0.009），与对照组相比，这可能表明其致癌活性。ROC分析显示miR-126可能是一个潜在的诊断标记。总之，miR-126的致癌行为提示其在乳腺癌患者的发病机制中的作用。
